ABSTRACT
Today, intravenous immunoglobulin (IVIG) preparations produced under strict adherence to ‘good manufacturing practice’ (GMP) can be considered to provide very low risk for transmission of blood-borne pathogens. However, the above statement can only be made today because of considerable efforts by industry and authorities over the past 20 years. The pathogens that are relevant in the context of IVIG safety are those that can-at least theoretically-be transmitted by transfusions (Table 1).
